Cat. No.: HY-B0580C

Ketorolac hemicalcium

(Synonyms: RS37619 hemicalcium)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Ketorolac (RS37619) hemicalcium is a non-steroidal anti-inflammatory drug (NSAID), acting as a nonselective COX inhibitor, with IC₅₀s of 20 nM for COX-1 and 120 nM for COX-2. Ketorolac tromethamine is used as 0.5% ophthalmic solution for the research of allergic conjunctivitis, cystoid macular edema, intraoperative miosis, and postoperative ocular inflammation and pain. Ketorola chemicalcium is also a DDX3 inhibitor that can be used for cancer research.

For research use only. We do not sell to patients.

Purity: 98.06%
CAS No.: 167105-81-9
Formula: C₁₅H₁₂CaNO₃⁺
Molecular Weight:274.31

Storage:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

Ketorolac hemicalcium Chemical Structure

CAS No.: 167105-81-9

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

All COX Isoforms :

In Vitro

Ketorolac (RS37619) salt (0-30 μM; 48 h) effectively kills the oral cancer cells^[4].
Ketorolac salt (0-5 μM; 48 h) inhibits the expression of DDX3 protein, and induces apoptosis in H357 cells^[4].
Ketorolac salt (0-2.5 μM; 0-16 h) inhibits the proliferation of oral cancer cells^[4].
Ketorolac salt (0-50 μM) directly interacts with DDX3 and inhibits the ATPase activity^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

HOK, SCC4, SCC9 and H357 cells
Concentration:

0-30 μM
Incubation Time:

48 h
Result:

Showed inhibition with IC₅₀s of 2.6, 7.1 and 8.1 μM against H357, SCC4 and SCC9 cells, respectively. And the normal HOK cell line did not show any cell death effect.

Cell Proliferation Assay^[4]

Cell Line:

H357
Concentration:

0.5, 1.0, 1.5, 2.0 and 2.5 μM
Incubation Time:

0, 8 and 16 h
Result:

Inhibited the proliferation.

Western Blot Analysis^[4]

Cell Line:

H357
Concentration:

1, 2.5 and 5 μM
Incubation Time:

48 h
Result:

Significantly reduced DDX3 protein expression levels, but not completely ablated as compared to DMSO treated cells. Up regulated the expression of E-cadherin.

Apoptosis Analysis^[4]

Cell Line:

H357
Concentration:

2.5 and 5 μM
Incubation Time:

48 h
Result:

Induced apoptosis.

In Vivo

Ketorolac (RS37619) (0.4% ketorolac tromethamine ophthalmic solution) shows powerful ocular anti-inflammatory activities in rabbits^[1].
Ketorolac (4 mg/kg/day, p.o.; 2 weeks) has no detrimental effect in the volume fraction of bone trabeculae formed inside the alveolar socket in rats^[2].
Ketorolac (60 μg; intrathecal injection; once) attenuates the damage caused by spinal cord ischemia in rats^[3].
Ketorolac salt (20 and 30 mg/kg; i.p.; two times in a week for 3 weeks) reduces oral carcinogenesis in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

New Zealand White rabbits (2.0–2.7 kg), LPS endotoxin-induced ocular inflammation^[1]
Dosage:

50 μL ketorolac tromethamine ophthalmic solution 0.4%
Administration:

In eyes, twice, 2 hours and 1 hour before LPS challenge
Result:

Resulted in a nearly complete inhibition (98.7%) of LPS endotoxin-induced increases in FITC (fluorescein isothiocyanate)-dextran in the anterior chamber, and resulted in a nearly complete inhibition (97.5%) of LPS endotoxin-induced increases in aqueous PGE₂ concentrations in the aqueous humor.

Animal Model:

Male Wistar rats (400–450 g), spinal cord ischemia model^[3]
Dosage:

30 and 60 μg
Administration:

Intrathecal injection, 1 h before the ischemia induction for once
Result:

Significantly reduced the motor disturbances and improved the survival rate at 60 μg.

Animal Model:

BALB/c mice, oral carcinogenesis model^[4]
Dosage:

20 mg/kg and 30 mg/kg
Administration:

IP injection, two times in a week for 3 weeks
Result:

Decreased tumor burden, reduced expression of DDX3 and anti-apoptotic proteins (Bcl-2 and Mcl-1).

Chemical Information

CAS No. 167105-81-9
Appearance Solid
Molecular Weight 274.31
Formula C₁₅H₁₂CaNO₃⁺
Color White to off-white
SMILES

O=C(C1C2=CC=C(C(C3=CC=CC=C3)=O)N2CC1)[O-].[Ca+2].[0.5]
Synonyms

RS37619 hemicalcium
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

BMC Anesthesiol

Inflammation and macrophage infiltration exacerbate adult incision response by early life injury. [Abstract]

2025 Apr 10;25(1):165. PMID: 40211125

Solvent & Solubility

In Vitro:

DMSO : 14.29 mg/mL (52.09 mM; ultrasonic and adjust pH to 3 with 1 M HCl and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.6455 mL

18.2276 mL

36.4551 mL

5 mM

0.7291 mL

3.6455 mL

7.2910 mL

10 mM

0.3646 mL

1.8228 mL

3.6455 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (288 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Waterbury LD, et al. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40. [Content Brief]

[2]. Fracon RN, et al. Treatment with paracetamol, ketorolac or etoricoxib did not hinder alveolar bone healing: a histometric study in rats. J Appl Oral Sci. 2010 Dec;18(6):630-4. [Content Brief]

[3]. Hsieh YC, et al. Intrathecal ketorolac pretreatment reduced spinal cord ischemic injury in rats. Anesth Analg. 2005 Apr;100(4):1134-9. [Content Brief]

[4]. Samal SK, et al. Ketorolac salt is a newly discovered DDX3 inhibitor to treat oral cancer. Sci Rep. 2015 Apr 28;5:9982. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.6455 mL	18.2276 mL	36.4551 mL	91.1378 mL
	5 mM	0.7291 mL	3.6455 mL	7.2910 mL	18.2276 mL
	10 mM	0.3646 mL	1.8228 mL	3.6455 mL	9.1138 mL
	15 mM	0.2430 mL	1.2152 mL	2.4303 mL	6.0759 mL
	20 mM	0.1823 mL	0.9114 mL	1.8228 mL	4.5569 mL
	25 mM	0.1458 mL	0.7291 mL	1.4582 mL	3.6455 mL
	30 mM	0.1215 mL	0.6076 mL	1.2152 mL	3.0379 mL
	40 mM	0.0911 mL	0.4557 mL	0.9114 mL	2.2784 mL
	50 mM	0.0729 mL	0.3646 mL	0.7291 mL	1.8228 mL

Keywords

Ketorolac hemicalcium

1 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ketorolac hemicalcium

Apoptosis Compound Library

Immunology/Inflammation Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Pancreatic Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

Protein-protein Interaction Inhibitor Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Off-patent Drug Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Ketorolac hemicalcium

All COX Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ketorolac hemicalcium Related Classifications

Cat. No.: HY-B0580C